Edgar Filing: PharMerica CORP - Form DEFA14A

PharMerica CORP
Form DEFA14A
August 02, 2017

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934

Filed by the Registrant x
Filed by a Party other than the Registrant "

Check the appropriate box:

- "Preliminary Proxy Statement
- "Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- "Definitive Proxy Statement
- " Definitive Additional Materials

x Soliciting Material Pursuant to § 240.14a-12

PHARMERICA CORPORATION

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

x No fee required.

[&]quot;Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

Edgar Filing: PharMerica CORP - Form DEFA14A

(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
(4)Proposed maximum aggregate value of transaction:
(5)Total fee paid:
"Fee paid previously with preliminary materials. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for "which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement No.:
(3)Filing Party:
(4)Date Filed:

Edgar Filing: PharMerica CORP - Form DEFA14A

EXHIBIT INDEX

Exhibit Number	Description
99.1	Letter sent to PharMerica Corporation clients
99.2	Letter and FAQ sent to PharMerica Corporation employees
99.3	Client talking points
99.4	PharMerica Corporation senior leaders communications toolkit
99.5	Letter and FAQ sent to Amerita, Inc. employees
99.6	Letter and FAQ sent to OncoMed Specialty, LLC employees